Key facts
- Seda Pharmaceutical Development Services’s last known valuation is $1.0M (Apr 2019).
- It has raised $20.3M; the latest was PE Growth/Expansion ($20.1M) in Mar 2026.
- Notable investors include BGF (Financial Services).
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Seda Pharmaceutical Development Services
- ·The full record, as it builds
Funding rounds
No funding rounds for Seda Pharmaceutical Development Services are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Seda Pharmaceutical Development Services
Provider of pharmaceutical development and clinical pharmacology management services intended to maximize the value of development assets. The company specializes in drug substance project strategy development, drug formulation, quality target product profile, quality risk assessment, clinical trials, physicochemical characterization, chemical and physical stability studies, scaling and prediction of human pharmacokinetics and other related services, enabling pharma and biotechnology industries to support longer-term expansion strategy and clinical investment decisions.
- Sector
- Healthcare
- HQ
- Greater Manchester, United Kingdom
- Founded
- 2015
- Employees
- 50
- Website
- sedapds.com/
- Ownership
- Privately Held (backing)
Seda Pharmaceutical Development Services doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Seda Pharmaceutical Development Services shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Seda Pharmaceutical Development Services in its N-PORT filings yet. We sweep new filings monthly.